Skip to content

YPOG advises investor consortium led by INKEF Capital on €64 million financing round of Cardior

Dr. Martin<br>Schaper Dr. Martin
Dr. Malte<br>Bergmann Dr. Malte
Dr. Ansgar<br>Frank Dr. Ansgar
Dr. Martyna<br>Sabat Dr. Martyna
Ann-Kristin <br>Lochmann Ann-Kristin
Pia<br>Meven Pia
Jonas<br>Huth Jonas
Lukas<br>Schmitt Lukas

Berlin – A Team led by partner Martin Schaper provided comprehensive legal and tax advice to a consortium of investors led by INKEF Capital on the investment in the Series B financing round of Hanover-based Cardior Pharmaceuticals. The round has a volume of € 64 million. In addition to lead investor INKEF, new investors Fund+, Sunstone, Hadean Ventures and Coparion participated in the round. In addition, existing investors such as LSP, BioMedPartners, Bristol Myers Squibb and High-Tech Gründerfonds also participated in the financing round. In connection with the financing, representatives from INKEF Capital, Fund+ and Sunstone will join the company’s advisory board. Cardior Pharmaceuticals is a leading clinical-stage biopharmaceutical company pioneering the discovery and development of RNA-based therapeutics designed to prevent, repair and reverse diseases of the heart. Cardior’s therapeutic approach uses distinctive non-coding RNAs as an innovative platform for addressing the root causes of cardiac dysfunctions. The company aspires to bring transformative therapeutics and diagnostics to patients and thereby make a lasting impact on the treatment of cardiac diseases worldwide. The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program and the expansion of the company’s earlier-stage pipeline.
INKEF Capital is an Amsterdam-based venture capital firm backing promising early-stage companies in Europe with a portfolio of more than 45 companies in the healthcare and technology sectors.

Download PDF


Dr. Martin Schaper (Lead), Partner
Dr. Malte Bergmann, Partner
Dr. Martyna Sabat, Senior Associate
Dr. Ansgar Frank, Associated Partner
Ann-Kristin Lochmann, Senior Associate
Pia Meven, Associate
Jonas Huth, Associate
Lukas Schmitt, Associate

The law firm KNPZ (Dr. Kai Plath, Matthias Struck and Jan Schäfer) advised on the transaction alongside the YPOG Team on IP aspects.

About us

YPOG is a boutique law firm for tax and business law which is active in the core fields of Tax, Funds, Corporate, Litigation, Transactions, IP/IT and notarial services. The Team at YPOG represents a broad client base, which ranges from emerging technology companies and family-run SMEs to large corporations as well as private equity and venture capital funds. YPOG is one of the leading players for venture capital, private equity and fund structuring in Germany. The firm and its partners have been recognized nationally and internationally by JUVE, Best Lawyers, Legal 500, Focus and Chambers and Partners. Today, YPOG has more than 70 experienced lawyers and tax specialists and a notary, in three offices in Berlin, Hamburg and Cologne. More information about YPOG: and